259 related articles for article (PubMed ID: 31058792)
21. The clinical impact of Stenotrophomonas maltophilia bacteremia on the 30-day mortality rate in patients with hematologic disorders: a single-institution experience.
Bao H; Qiao Y; Liu D; Chen J; Wu X; Hu X; Ma X; Wu D
Infection; 2020 Apr; 48(2):205-212. PubMed ID: 31686323
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
Junco SJ; Bowman MC; Turner RB
Int J Antimicrob Agents; 2021 Aug; 58(2):106367. PubMed ID: 34058337
[TBL] [Abstract][Full Text] [Related]
23. Stenotrophomonas maltophilia: An emerging opportunistic nosocomial pathogen in a tertiary care hospital in Al Batinah North Governorate, Oman.
Sannathimmappa MB; Nambiar V; Aravindakshan R; Al-Kasaby NM
Sultan Qaboos Univ Med J; 2021 Feb; 21(1):e66-e71. PubMed ID: 33777425
[TBL] [Abstract][Full Text] [Related]
24. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.
Cho SY; Lee DG; Choi SM; Park C; Chun HS; Park YJ; Choi JK; Lee HJ; Park SH; Choi JH; Yoo JH
BMC Infect Dis; 2015 Feb; 15():69. PubMed ID: 25887489
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017.
Wang L; Zhou W; Cao Y; Yang C; Liu H; Chen T; Chen L
Medicine (Baltimore); 2020 Feb; 99(8):e19250. PubMed ID: 32080131
[TBL] [Abstract][Full Text] [Related]
26. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review.
Garazi M; Singer C; Tai J; Ginocchio CC
J Hosp Infect; 2012 Jun; 81(2):114-8. PubMed ID: 22494851
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia.
Jeon YD; Jeong WY; Kim MH; Jung IY; Ahn MY; Ann HW; Ahn JY; Han SH; Choi JY; Song YG; Kim JM; Ku NS
Medicine (Baltimore); 2016 Aug; 95(31):e4375. PubMed ID: 27495046
[TBL] [Abstract][Full Text] [Related]
28. [Risk factors and clinical charasteristics of Stenotrophomonas maltophilia bacteremia: a comparison with bacteremia due to other glucose-non fermenters].
Hotta G; Matsumura Y; Kato K; Nakano S; Yunoki T; Yamamoto M; Nagao M; Ito Y; Takakura S; Ichiyama S
Kansenshogaku Zasshi; 2013 Sep; 87(5):596-602. PubMed ID: 24195169
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors of Stenotrophomonas maltophilia Blood Stream Infections: Comparison With Other Gram-Negative Blood Stream Infections in Children.
Gayretli Aydιn ZG; Tanir G; Bayhan GI; Aydin Teke T; Metin Akçan O; Kaman A; Yasar Durmus S; Oz FN
Pediatr Infect Dis J; 2020 Dec; 39(12):e406-e409. PubMed ID: 33214406
[TBL] [Abstract][Full Text] [Related]
30. Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years.
Velázquez-Acosta C; Zarco-Márquez S; Jiménez-Andrade MC; Volkow-Fernández P; Cornejo-Juárez P
Support Care Cancer; 2018 Jun; 26(6):1953-1960. PubMed ID: 29307014
[TBL] [Abstract][Full Text] [Related]
31. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.
Samonis G; Karageorgopoulos DE; Maraki S; Levis P; Dimopoulou D; Spernovasilis NA; Kofteridis DP; Falagas ME
PLoS One; 2012; 7(5):e37375. PubMed ID: 22624022
[TBL] [Abstract][Full Text] [Related]
32. Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.
Lee JY; Kang CI; Ko JH; Lee WJ; Seok HR; Park GE; Cho SY; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
Antimicrob Agents Chemother; 2016 Nov; 60(11):6673-6678. PubMed ID: 27572416
[TBL] [Abstract][Full Text] [Related]
33. Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.
Juhász E; Krizsán G; Lengyel G; Grósz G; Pongrácz J; Kristóf K
Ann Clin Microbiol Antimicrob; 2014 Dec; 13():333. PubMed ID: 25551459
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for hospital acquisition of trimethoprim-sulfamethoxazole resistant Stenotrophomonas maltophilia in adults: A matched case-control study.
Wang CH; Lin JC; Chang FY; Yu CM; Lin WS; Yeh KM
J Microbiol Immunol Infect; 2017 Oct; 50(5):646-652. PubMed ID: 28688829
[TBL] [Abstract][Full Text] [Related]
35. [Nosocomial Stenotrophomonas maltophilia infections in a university hospital].
Caylan R; Yilmaz G; Sucu N; Bayraktar O; Aydin K; Kaklikkaya N; Aydin F; Köksal I
Mikrobiyol Bul; 2005 Jan; 39(1):25-33. PubMed ID: 15900834
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for mortality in
Huang C; Lin L; Kuo S
Infect Dis (Lond); 2024 May; 56(5):335-347. PubMed ID: 38436567
[TBL] [Abstract][Full Text] [Related]
37. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures.
Kwa AL; Low JG; Lim TP; Leow PC; Kurup A; Tam VH
Ann Acad Med Singap; 2008 Oct; 37(10):826-30. PubMed ID: 19037515
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Doxycycline or Minocycline to Sulfamethoxazole-Trimethoprim for Treatment of
Alhayani T; Philpott CD; Liao S; Gentene AJ; Mueller EW
Ann Pharmacother; 2024 Jan; 58(1):21-27. PubMed ID: 37125743
[TBL] [Abstract][Full Text] [Related]
39. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan.
Wang WS; Liu CP; Lee CM; Huang FY
J Microbiol Immunol Infect; 2004 Dec; 37(6):359-65. PubMed ID: 15599468
[TBL] [Abstract][Full Text] [Related]
40. Bloodstream infection caused by Stenotrophomonas maltophilia in children.
Kagen J; Zaoutis TE; McGowan KL; Luan X; Shah SS
Pediatr Infect Dis J; 2007 Jun; 26(6):508-12. PubMed ID: 17529868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
